Leukemogenesis, hematopoietic toxicity, development
Hematopoiesis, bone marrow, hemogenic endothelium
HSCs, iPSCs-derived blood cells, RNA binding proteins, transcription factors
Focus Groups: Hematopoiesis; Cancer Stem Cells;
Research description: Basic/Translational
Understanding the fundamental molecular and cellular mechanisms of normal and malignant hematopoiesis using genetically modified mouse models and pluripotent stem cells. The ongoing research projects include hiPSCs-based in vitro systems for hematopoietic toxicity screens, and studies of IGF2BP1 RNA-binding protein in normal hematopoietic development and leukemia using Igf2bp1LoxP conditional knockout mice.
Technical expertise: mESCs/iPSCs isolation and characterization, differentiation of human and mouse PSCs to various lineages; mouse BM progenitor cells;
- Elcheva I, Brok-Volchanskaya V, Kumar A, Liu P, Lee JH, Tong L, Vodyanik M, Swanson S, Stewart R, Kyba M, Yakubov E, Cooke J, Thomson JA, Slukvin I. Direct induction of haematoendothelial programs in human pluripotent stem cells by transcriptional regulators. Nat Commun. 2014 Jul 14; 5:4372.
- Elcheva I, Goswami S, Noubissi FK, Spiegelman VS. CRD-BP protects the coding region of betaTrCP1 mRNA from miR-183-mediated degradation. Mol Cell. 2009 Jul 31; 35(2):240-6.
- Elcheva I, Tarapore RS, Bhatia N, Spiegelman VS. Overexpression of mRNA-binding protein CRD-BP in malignant melanomas. Oncogene. 2008 Aug 28; 27(37):5069-74.
- Noubissi FK, Elcheva I, Bhatia N, Shakoori A, Ougolkov A, Liu J, Minamoto T, Ross J, Fuchs SY, Spiegelman VS. CRD-BP mediates stabilization of betaTrCP1 and c-myc mRNA in response to beta-catenin signalling. Nature. 2006 Jun 15; 441(7095):898-901.